Litcius/Paper detail

High Response Rate and Corticosteroid Sparing with Arsenic Trioxide-Based First-Line Therapy in Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation

Dominique Rongvaux-Gaïda, Maëva Dupuis, Joël Poupon, Nouzha Djebrani‐Oussedik, Catherine Lemonnier, François Rieger

2022Transplantation and Cellular Therapy10 citationsDOI

Topics & Concepts

MedicineArsenic trioxideClinical endpointHematopoietic stem cell transplantationTransplantationGraft-versus-host diseaseInternal medicineAdverse effectSurgeryPhases of clinical researchGastroenterologyClinical trialArsenicMaterials scienceMetallurgyRetinoids in leukemia and cellular processesHematopoietic Stem Cell TransplantationAcute Myeloid Leukemia Research
High Response Rate and Corticosteroid Sparing with Arsenic Trioxide-Based First-Line Therapy in Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation | Litcius